Federal fraudbusters focus on drug pricing while quest for Rx discount card continuesNovember 1st 2001
With the government spending billions to fight terrorism at home and abroad, federal investigators are looking closely at all health care programs for opportunities to stymie abuses and collect big penalties.
Dalteparin for enoxaparin interchange: Chart review shows promising clinical, economic outcomesOctober 1st 2001
University Hospital and Medical Center (Tamarac)/University of Florida (Gainesville)-Dalteparin appears to be at least as clinically effective as enoxaparin for the prevention or treatment of the consequences of venous and arterial thromboembolic diseases, say clinicians from these two facilities.
Florida-Pfizer deal charts new territory in overall cost control, but can it work?September 1st 2001
The unprecedented Medicaid disease management deal struck between Florida and Pfizer this summer represents an important "move past unit cost control into total disease control," according to Perry Cohen, PharmD.
Political climate could shed new light on Medicare pharmacy benefit, related issuesSeptember 1st 2001
A few weeks ago, it looked like the national economic slowdown, which was eroding the anticipated federal budget surplus, might put the costly Medicare pharmaceutical benefit on the endangered list. Congress was having trouble agreeing on a coverage plan, and interest groups were squabbling over how to craft a fair and effective pharmacy program for the elderly.
Fees and formularies move to center of Medicare Rx benefit debateAugust 1st 2001
Flush from victory in passing patients' rights legislation, Senate Democrats are expected to push for a Medicare prescription drug benefit this fall. The new Senate leadership seems to have found that championing health care is a winning strategy and is eager to build on its success.